Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02104921 · ClinicalTrials.gov registry record

Innovative Ultrasound Technology in Neuromuscular Disease

A clinical trial, sponsored by Beth Israel Deaconess Medical Center.

Completed
Registry status
223
Enrollment target

NCT02104921: Completed study, sponsored by Beth Israel Deaconess Medical Center.

NCT02104921 is a clinical trial that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 223 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02104921 has completed, sponsored by Beth Israel Deaconess Medical Center.

COMPLETED
Registry status
223 participants
Enrollment target

Study Summary

This study is utilizing ultrasound measurement to measure neuromuscular disease status in adult patients. The hypothesis is the by quantifying ultrasound data, it is possible that ultrasound can be utilized as a tool to determine if a disease is responding to therapy or progressing.

Primary Outcome

Ultrasound data will be collected on multiple muscles in each person. The images will then be quantified using either 1. A grayscale technique in which the images themselves are analyzed via standard image software (e.g., Adobe Photoshop) as to level of echo intensity in a pre-specific region of interest or 2. the raw quantified backscatter data is captured by the transducer, expressed as a unit of power, in the same pre-specified area of interest

Trial Details

FieldValue
Enrollment Target 223 participants
Start Date 2013-12-01
Est. Completion 2020-03-01

What the finished NCT02104921 record still lists

NCT02104921 is an observational study that tracks outcomes without assigning an intervention. The registered 223 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT02104921 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02104921 about?

NCT02104921 is a clinical study titled "Innovative Ultrasound Technology in Neuromuscular Disease". This study is utilizing ultrasound measurement to measure neuromuscular disease status in adult patients. The hypothesis is the by quantifying ultrasound data, it is possible that ultrasound can be utilized as a tool to determine if a disease is responding to therapy or progressing.

What is the current status of trial NCT02104921?

This trial is currently completed. The enrollment target is 223 participants. The study started on 2013-12-01. Estimated completion is 2020-03-01.

Who is sponsoring clinical trial NCT02104921?

This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06640803 · 223 participants · NA

    Sacramento Clinical High Risk for Psychosis Stepped-Care Program

  • NCT07175285 · 223 participants

    A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

  • NCT07205718 · 223 participants · Phase 1

    A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

  • NCT02706561 · 224 participants · NA

    Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02104921, the US trial registry maintained by the National Library of Medicine. NCT02104921 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.